Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
about
Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyPathophysiology and preventive strategies of anthracycline-induced cardiotoxicityPrevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprololCardiac toxicity in cancer survivorsCardiac effects of anticancer therapy in the elderlyCancer survivors in the United States: a review of the literature and a call to actionSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsCardiac risk in the treatment of breast cancer: assessment and management.Current Views on Anthracycline Cardiotoxicity in Childhood Cancer SurvivorsChemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionNoninvasive diagnosis of chemotherapy related cardiotoxicityDiscovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven ApproachCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionEarly Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Nuclear imaging in detection and monitoring of cardiotoxicity.Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumabChemotherapy-induced cardiomyopathy in breast cancer patients.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Cardiotoxicity and oncological treatments.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumabRole of echocardiography in the management of cardiac disease in women.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesCardiovascular complications of breast cancer therapy in older adultsBiweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathyClinical outcomes of extracorporeal membrane oxygenation support in patients with hematologic malignancies.Clinical cardiac safety profile of nilotinib.Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patientsProtective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy.Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordAssociation of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphismsCancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).Extracellular ATP protects endothelial cells against DNA damage.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)
P2860
Q26740352-DBCD2A22-6A50-49A2-8FA4-1E4100179A73Q26743433-3DCF8E86-20A8-4DC6-8AF9-8B14CE1398DEQ26744675-82EB436D-2A91-4CF3-A095-5B2AE5EDE60CQ26768272-A182CB4E-D703-432C-8B49-3508D17FDB19Q26851957-E65DB4D1-C3D9-411C-9F75-2F2FB7CA352BQ26863244-559CD22A-C387-4733-94FB-C73ACC7685EAQ26865247-69136BBD-5ED5-487E-BF00-C7B4720E7718Q27007849-9F571689-1605-451E-82B4-9784135D4218Q28081385-B9957316-8819-414D-BBC9-B6E43F91D673Q28083073-9AFB0772-5293-4397-A76C-CDA335CB4FB2Q30399577-491392CD-79D6-41CE-A897-8ACA817F2223Q30461444-30242653-0533-4F6F-954A-545C2409B834Q31140868-8E1A520E-71EF-4CDD-BEB4-5CF79A1D09E3Q33574045-3DFAFD3B-DB89-40C5-A337-072DE794C633Q33752979-2172B873-E393-4599-BE04-1A96DCBEF0CDQ33942611-6905C1B6-E670-4D27-BF64-FC2DD30D2984Q34172962-B1FB2729-25FA-4264-96A6-FFABC0F6ECB5Q34292469-4EEED784-0DA9-4368-8E60-B3B2C4DF4231Q34474264-4F17075C-50C0-4908-A741-067A297330C8Q34621237-FE033D95-ACC3-4217-9FB7-B68A209C5441Q34626238-90097622-2BE6-478D-9707-FFFC7B1F8AB0Q34660647-883DEFDB-8127-4494-8D95-DE84254D3F49Q34724614-AD4F940D-B971-4B03-A0FB-C8C64CACC9EDQ34855776-04E65919-2AEE-461C-9CFB-6206BA36144EQ34863501-73B847DD-8AFB-4856-8D56-2A459769D233Q35008126-6F9A0E3B-F6F8-4E80-90EE-5627044D2D86Q35584182-3AB84DEE-C5ED-437A-BEA1-3618D99B7B8DQ35584686-2A49DDAF-668D-4338-8B9D-28F367FCDC97Q35673260-25B06A50-55B4-48AA-9555-9A5F2D9ECE8AQ35834945-F4F2B84B-1CD2-4777-8C47-336C045B0154Q36006389-48A96B3A-53C6-4484-ACBD-7C71A4EDF5B2Q36181301-92733BE4-8A7F-402D-AE5C-DD9CC395CED1Q36245459-87CC8BAA-7698-4F34-B56D-B23D011EF231Q36365075-D7CBFB93-C805-4173-9282-4D505D6354B0Q36721511-9BDD2273-773A-4AD2-A24C-57E7EE132CB1Q36804526-36842D92-5D4B-49B2-B746-153678C8ED7DQ36887091-42D03DC8-4CED-4D0E-AB83-8A2D50712EBAQ37116520-74C88074-676B-4670-B6F6-CA976F9D7597Q37256404-8F936514-5824-456E-B6F4-7E83FB6D38F7Q37260992-AE81E663-CBF5-4272-8616-56E84FD05EFF
P2860
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@en
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@nl
type
label
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@en
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@nl
prefLabel
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@en
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@nl
P2093
P1433
P1476
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
@en
P2093
Dirk J van Veldhuisen
Elisabeth Ge de Vries
Jourik A Gietema
Patrick J Perik
Renske Altena
P304
P356
10.1016/S1470-2045(09)70042-7
P577
2009-04-01T00:00:00Z